WO1999001124A9 - Synthesis of epothilones, intermediates thereto, analogues and uses thereof - Google Patents
Synthesis of epothilones, intermediates thereto, analogues and uses thereofInfo
- Publication number
- WO1999001124A9 WO1999001124A9 PCT/US1997/022381 US9722381W WO9901124A9 WO 1999001124 A9 WO1999001124 A9 WO 1999001124A9 US 9722381 W US9722381 W US 9722381W WO 9901124 A9 WO9901124 A9 WO 9901124A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- linear
- substituted
- branched
- compound
- alkyl
- Prior art date
Links
- 0 CC([C@](CC=C(*)*)O*)=Cc1c[s]c(C)n1 Chemical compound CC([C@](CC=C(*)*)O*)=Cc1c[s]c(C)n1 0.000 description 8
- SAMXUQPRBXCGFQ-IOCXFXADSA-N C/C(/[C@H](CC=C)O)=C\c1c[s]c(C)n1 Chemical compound C/C(/[C@H](CC=C)O)=C\c1c[s]c(C)n1 SAMXUQPRBXCGFQ-IOCXFXADSA-N 0.000 description 1
- NTRQOTNFDKYZFB-UHFFFAOYSA-N CCC1=[O]CC[O]1=C Chemical compound CCC1=[O]CC[O]1=C NTRQOTNFDKYZFB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the present invention is in the field of epothilone macrolides.
- the present invention relates to processes for the preparation of epothilones A and B, desoxyepothilones A and B, and analogues thereof which are useful as highly specific, non- toxic anticancer therapeutics.
- the invention provides methods of inhibiting multidrug resistant cells.
- the present invention also provides novel compositions of matter which serve as intermediates for preparing the epothilones.
- Epothilones A and B are highly active anticancer compounds isolated from the Myxobacteria of the genus Sorangium. The full structures of these compounds, arising from an x-ray crystal lographic analysis were determined by H ⁇ fle. C. H ⁇ fle et al., Angew. Chem. Int. Ed. Engl., 1996, 35, 1567. The total synthesis of the epothilones is an important goal for several reasons. Taxol is already a useful resource in chemotherapy against ovarian and breast cancer and its range of clinical applicability is expanding. C.I. Ceorg et al., Taxane Anticancer Agents; American Cancer Society: San Diego, 1995.
- the present invention also provides novel intermediates useful in the synthesis of epothilones A and B and analogues thereof, compositions derived from such epothilones and analogues, purified compounds of epothilones A and B, and desoxyepothilones A and B, in addition to methods of use of the epothilone analogues in the treatment of cancer.
- certain epothilones have been found to be effective not only in reversing multi-drug resistance in cancer cells, both in vitro and in vivo, but have been determined to be active as collateral sensitive agents, which are more cytotoxic towards MDR cells than normal cells, and as synergistic agents, which are more active in combination with other cytotoxic agents, such as vinblastin, than the individual drugs would be alone at the same concentrations.
- the desoxyepothilones of the invention have exceptionally high specificity as tumor cytotoxic agents in vivo, more effective and less toxic to normal cells than the principal chemotherapeutics currently in use, including taxol, vinblastin, adriamycin and camptothecin.
- a further object of the present invention is to provide synthetic methods for preparing such intermediates.
- An additional object of the invention is to provide compositions useful in the treatment of subjects suffering from cancer comprising any of the analogues of the epothilones available through the preparative methods of the invention optionally in combination with pharmaceutical carriers.
- a further object of the invention is to provide methods of treating subjects suffering from cancer using any of the analogues of the epothilones available through the preparative methods of the invention optionally in combination with pharmaceutical carriers.
- Figure 1(A) shows a retrosynthetic analysis for epothilone A and B.
- Figure 1(B) provides synthesis of compound 11.
- Phl(OCOCF 3 ) 2 MeOH/THF, rt, 0.25 h, 92%.
- Figure 2 provides key intermediates in the preparation of 12,13-f- and -Z-deoxyepothilones.
- Figure 3(A) provides syntheses of key iodinated intermediates used to prepare hydroxymethylene- and hydroxypropylene-substituted epothilone derivatives.
- Figure 3(B) provides methods of preparing hydroxymethylene- and hydroxypropylene- substituted epothilone derivatives, said methods being useful generally to prepare 12,13-f epothilones wherein R is methyl, ethyl, n-propyl, and n-hexyl from the corresponding f-vinyl iodides.
- Figure 3(B) shows reactions leading to benzoylated hydroxymethyl-substituted desoxyepothilone and hydroxymethylene-substituted epothilone (epoxide).
- Figure 4(A) provides synthesis of compound 19.
- Figure 5 shows a scheme of the synthesis of the "left wing" of epothilone A.
- Figure 6 provides a scheme of an olefin metathesis route to epothilone A and other analogues.
- Figure 7 illustrates a convergent strategy for a total synthesis of epothilone A (1) and the glycal cyclopropane solvolysis strategy for the introduction of geminal methyl groups.
- Figure 8 provides an enantioselective synthesis of compound 15B.
- Figure 9 shows the construction of epothilone model systems 20B, 21B, and 22B by ring- closing olefin metathesis.
- Figure 10 illustrates a sedimentation test for natural, synthetic and desoxyepothilone A.
- Figure 11 illustrates a sedimentation test for natural, synthetic and desoxyepothilone A after cold treatment at 4°C.
- Figure 12 illustrates (A) structures of epothilones A (1) and B (2) and (B) of TaxolTM (1A).
- Figure 13 shows a method of elaborating acyclic stere ⁇ chemical relationships based on dihydropyrone matrices.
- Figure 14 shows the preparation of intermediate 4A.
- Figure 15 shows an alternative enantioselective synthesis of compound 17A.
- Figure 16 provides a synthetic pathway to intermediate 13C.
- (a) 1. tributyl allyltin, (S)-(-)- BINOL, Ti(0/-Pr) 4 , CH 2 CI 2 , -20 °C, 60%, > 95% e.e.; 2. Ac 2 0, Et 3 N, DMAP, CH 2 CI 2 , 95%;
- (b) 1. Os0 4 , NMO, acetone/H 2 0, 0°C; 2.
- Figure 18 provides a synthetic pathway to a protected intermediate for 8-desmethyl deoxyepothilone A.
- Figure 19 provides a synthetic pathway to 8-desmethyl deoxyepothilone A, and structures of trans-8-desmethyl-desoxyepothiolone A and a trans-iodoolefin intermediate thereto.
- Figure 20 shows (top) structures of epothilones A and B and 8-desmethylepothilone and (bottom) a synthetic pathway to intermediate TBS ester 10 used in the preparation of desmethylepothilone A.
- Figure 21 shows a synthetic pathway to 8-desmethylepothilone A.
- Figure 22 shows a synthetic pathway to prepare epothilone analogue 27D.
- Figure 23 shows a synthetic pathway to prepare epothilone analogue 24D.
- Figure 24 shows a synthetic pathway to prepare epothilone analogue 19D.
- Figure 25 shows a synthetic pathway to prepare epothilone analogue 20D.
- Figure 26 shows a synthetic pathway to prepare epothilone analogue 22D.
- Figure 27 shows a synthetic pathway to prepare epothilone analogue 12-hydroxy ethyl- epothilone.
- Figure 28 shows the activity of epothilone analogues in a sedimentation test in comparison with DMSO, epothilone A and/or B. Structures 17-20, 22, and 24-27 are shown in Figures 29-37, respectively. Compounds were added to tubulin (1 mg/ml) to a concentration of 10 ⁇ M. The quantity of microtubules formed with epothilone A was defined as 100%.
- Figure 29 shows a high resolution ⁇ NMR spectrum of epothilone analogue #1 .
- Figure 30 shows a high resolution 'H NMR spectrum of epothilone analogue #18.
- Figure 31 shows a high resolution 1 H NMR spectrum of epothilone analogue #19.
- Figure 32 shows a high resolution 'H NMR spectrum of epothilone analogue #20.
- Figure 33 shows a high resolution 1 H NMR spectrum of epothilone analogue #22.
- Figure 34 shows a high resolution 'H NMR spectrum of epothilone analogue #24.
- Figure 35 shows a high resolution 'H NMR spectrum of epothilone analogue #25.
- Figure 36 shows a high resolution 1 H NMR spectrum of epothilone analogue #26.
- Figure 37 shows a high resolution 'H NMR spectrum of epothilone analogue #27.
- Figure 38 provides a graphical representation of the effect of fractional combinations of cytotoxic agents.
- Figure 39 shows epothilone A and epothilone analogues #1-7. Potencies against human leukemia CCRF-CEM (sensitive) and CCRF-CEM/VBL MDR (resistant) sublines are shown in round and square brackets, respectively.
- Figure 40 shows epothilone B and epothilone analogues #8-16. Potencies against human leukemia CCRF-CEM (sensitive) and CCRF-CEM/VBL MDR (resistant) sublines are shown in round and square brackets, respectively.
- Figure 41 shows epothilone analogues #17-25. Potencies against human leukemia CCRF-CEM (sensitive) and CCRF-CEM/VBL MDR (resistant) sublines are shown in round and square brackets, respectively.
- Figure 42(A) shows epothilone analogues #26-34. Potencies against human leukemia CCRF- CEM (sensitive) and CCRF-CEM/VBL MDR (resistant) sublines are shown in round and square brackets, respectively.
- Figure 42(B) shows epothilone analogues #35-46. Potencies against human leukemia CCRF- CEM (sensitive) and CCRF-CEM/VBL MDR (resistant) sublines are shown in round and square brackets, respectively.
- Figure 42(C) shows epothilone analogues #47-49.
- Figure 43(A) shows antitumor activity of desoxyepothilone B against MDR MCF-7/Adr xenograft in comparison with taxol.
- Control ⁇
- desoxyepothilone B ⁇ ; 35mg/kg
- taxol ⁇ * ⁇ ; 6mg/kg
- adriamycin x;1.8mg/kg
- i.p. Q2Dx5 start on day 8.
- Figure 43(B) shows antitumor activity of epothilone B against MDR MCF-7/Adr xenograft in comparison with taxol.
- Control ⁇
- epothilone B ⁇ ; 25mg/kg; non-toxic dose
- taxol *; 6mg/kg; half LD 50
- adriamycin x;1.8mg/kg
- i.p. Q2Dx5 start on day 8.
- Figure 44(A) shows toxicity of desoxyepothilone B in B6D2F, mice bearing B16 melanoma. Body weight was determined at 0, 2, 4, 6, 8, 10 and 12 days. Control (*); desoxyepothilone B (o; 10mg/kg QDx ⁇ ; 0 of 8 died); desoxyepothilone B (•; 20mg/kg QDx6; 0 of 8 died). Injections were started on day 1.
- Figure 44(B) shows toxicity of epothilone B in B6D2F, mice bearing B16 melanoma. Body weight was determined at 0, 2, 4, 6, 8, 10 and 12 days. Control (*); epothilone B (°; 0.4mg/kg
- Figure 45(A) shows comparative therapeutic effect of desoxyepothilone B and taxol on nude mice bearing MX-1 xenoplant.
- Figure 45(B) shows comparative therapeutic effect of desoxyepothilone B and taxol on nude mice bearing MX-1 xenoplant.
- Taxol ⁇ ; 5mg/kg, one half of LD 50 , given on days 7, 9, 1 1 , 13, 15; then 6 mg/kg, given on days 17. 19, 23, 24, 25
- Figure 46 shows the effect of treatment with desoxyepothilone B (35 mg/kg), taxol (5 mg/kg) and adriamycin (2mg/kg) of nude mice bearing human MX-1 xenograft on tumor size between 8 and 18 days after implantation.
- Desoxyepothilone B (o), taxol ( ⁇ ), adriamycin (X), control ( ⁇ ); i.p. treatments were given on day 8, 10, 12, 14 and 16.
- Figure 47 shows the relative toxicity of epothilone B ( ⁇ ; 0.6 mg/kg QDx4; i.p.) and desoxyepothilone B ( ⁇ ; 25 mg/kg QDx4; i.p.) versus control ( ⁇ ) in normal nude mice.
- Body weight of mice was determined daily after injection.
- 8 of 8 mice died of toxicity on days 5, 6, 6, 7, 7, 7, 7, and 7; for desoxyepothilone B, all six mice survived.
- Figure 48 shows a high resolution 'H NMR spectrum of epothilone analogue #43.
- Figure 49 shows a high resolution ' H NMR spectrum of epothilone analogue #45.
- Figure 50 shows a high resolution ⁇ NMR spectrum of epothilone analogue #46.
- Figure 51 shows a high resolution ' H NMR spectrum of epothilone analogue #47.
- Figure 52 shows a high resolution 'H NMR spectrum of epothilone analogue #48.
- linear or branched chain alkyl encompasses, but is not limited to, methyl, ethyl, propyl, isopropyl, t-butyl, sec-butyl, cyclopentyl or cyclohexyl.
- the alkyl group may contain one carbon atom or as many as fourteen carbon atoms, but preferably contains one carbon atom or as many as nine carbon atoms, and may be substituted by various groups, which include, but are not limited to, acyl, aryl, alkoxy, aryloxy, carboxy, hydroxy, carboxamido and/or N-acylamino moieties.
- alkoxycarbonyl encompass, but are not limited to, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, n- butoxycarbonyl, benzyloxycarbonyl, hydroxypropylcarbonyl, aminoethoxycarbonyl, sec- butoxycarbonyl and cyclopentyloxycarbonyl.
- acyl groups include, but are not limited to, formyl, acetyl, propionyl, butyryl and penanoyl.
- alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, n-butoxy, sec-butoxy and cyclopentyloxy.
- an "aryl” encompasses, but is not limited to, a phenyl, pyridyl, pyrryl, indolyl, naphthyl, thiophenyl or fury! group, each of which may be substituted by various groups, which include, but are not limited, acyl, aryl alkoxy, aryloxy, carboxy, hydroxy, carboxamido or N-acylamino moieties.
- aryloxy groups include, but are not limited to, a phenoxy, 2-methylphenoxy, 3-methylphenoxy and 2-naphthoxy.
- Examples of acyloxy groups include, but are not limited to, acetoxy, propanoyloxy, butyryloxy, pentanoyloxy and hexanoyloxy.
- the subject invention provides chemotherapeutic analogues of epothilone A and B, including a compound having the structure:
- R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl, CH 2 OH, or (CH 2 ) 3 OH.
- the invention also provides a compound having the structure:
- R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl or CH 2 OH.
- R is H, methyl, ethyl, n-propyl, n-butyl, CH 2 OH or (CH 2 ) 3 OH.
- the invention further provides a compound having the structure:
- the invention also provides a compound having the structure: 24
- the subject invention also provides various intermediates useful for the preparation of the chemotherapeutic compounds epithilone A and B, as well as analogues thereof. Accordingly, the invention provides a key intermediate to epothilone A and its analogues having the structure:
- R is hydrogen, a linear or branched acyl, substituted or unsubstituted aroyl or
- R' is hydrogen, methyl, ethyl, n-propyl, n-hexyl,
- the subject invention provides a compound of the above structure wherein R is acetyl and X is iodo.
- the subject invention also provides an intermediate having the structure:
- R ' and R' ' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR) 2 , (SR) 2 , -(O- (CH 2 ) n -0)-, -(0-(CH 2 ) n -S)- or -(S-(CH 2 ) n -S)-; and wherein n is 2, 3 or 4.
- Another analogue provided by the invention has the structure:
- R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl, CH 2 OH, or (CH 2 ) 3 OH.
- an analogue having the structure:
- R is H or methyl.
- the scope of the present invention includes compounds wherein the C 3 carbon therein possesses either an R or S absolute configuration, as well as mixtures thereof.
- the subject invention further provides an analogue of epothilone A having the structure:
- the subject invention also provides synthetic routes to prepare the intermediates for preparing epothilones. Accordingly, the invention provides a method of preparing a Z-iodoalkene ester having the structure:
- R is hydrogen, a substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises (a) coupling a compound having the structure:
- R ' and R ' ' are independently a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryl or benzyl, under suitable conditions to form a compound having the structure:
- step (b) deprotecting and acylating the Z-iodoalkene formed in step (b) under suitable conditions to form the Z-iodoalkene ester.
- the coupling in step (a) may be effected using a strong base such as n-BuLi in an inert polar solvent such as tetrahydrofuran (THF) at low temperatures, typically below -50°C, and preferably at -78°C.
- the treatment in step (b) may comprise sequential reaction with N-iodosuccinimide in the presence of Ag(l), such as silver nitrate, in a polar organic solvent such as acetone, followed by reduction conditions, typically using a hydroborating reagent, preferably using Cy 2 BH.
- Deprotecting step (c) involves contact with a thiol such as thiophenol in the presence of a Lewis acid catalyst, such as boron trifluoride-etherate in an inert organic solvent such as dichloromethane, followed by acylation with an acyl halide, such as acetyl chloride, or an acyl anhydride, such as acetic anhydride in the presence of a mild base such as pyridine and/or 4-dimethyaminopyridine (DMAP) in an inert organic solvent such as dichloromethane.
- a Lewis acid catalyst such as boron trifluoride-etherate
- an inert organic solvent such as dichloromethane
- acyl halide such as acetyl chloride
- an acyl anhydride such as acetic anhydride in the presence of a mild base
- DMAP 4-dimethyaminopyridine
- R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein X is a halogen, which comprises (a) oxidatively cleaving a compound having the structure:
- X is iodine.
- the oxidative step (a) can be performed using a mild oxidant such as osmium tetraoxide at temperatures of about 0°C, followed by treatment with sodium periodate, or with lead tetraacetate/sodium carbonate, to complete the cleavage of the terminal olefin, and provide a terminal aldehyde.
- Condensing step (b) occurs effectively with a variety of halomethylenating reagents, such as Wittig reagents.
- the subject invention further provides a method of preparing an optically pure compound having the structure:
- R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises: (a) condensing an allylic organometallic reagent with an unsaturated aldehyde having the structure:
- the allylic organometallic reagent is an allyl(trialkyl)stannane.
- the condensing step is effected using a reagent comprising a titanium tetraalkoxide and an optically active catalyst.
- the 1 ,2-addition to the unsaturated aldehyde may be performed using a variety of allylic organometallic reagents, typically with an allyltrialkylstannane, and preferably with allyltri-n-butylstannane, in the presence of chiral catalyst and molecular sieves in an inert organic solvent such as dichloromethane.
- the method may be practiced using titanium tetraalkoxides, such as titanium tetra-n- propoxide, and 5-(-)BINOL as the optically active catalyst.
- Alkylating or acylating step (b) is effected using any typical alkylating agent, such as alkylhalide or alkyl tosylate, alkyl triflate or alkyl mesylate, any typical acylating agent, such as acetyl chloride, acetic anhydride, benzoyl chloride or benzoyl anhydride, in the presence of a mild base catalyst in an inert organic solvent, such as dichloromethane.
- any typical alkylating agent such as alkylhalide or alkyl tosylate, alkyl triflate or alkyl mesylate
- any typical acylating agent such as acetyl chloride, acetic anhydride, benzoyl chloride or benzoyl anhydride
- a mild base catalyst in an inert organic solvent, such as dichloromethane.
- the subject invention also provides a method of preparing an open-chain aldehyde having the structure:
- R ' and R ' ' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises: (a) cross-coupling a haloolefin having the structure:
- R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, and X is a halogen, with a terminal olefin having the structure: wherein (OR'") 2 is (OR 0 ) 2 , (SR 0 ) 2 , -(0-(CH 2 ) n -0)-, -(0-(CH 2 ) n -S)- or -(S-(CH 2 ) n -S)- where R 0 is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; and wherein n is 2, 3 or 4, under suitable conditions to form a cross-coupled
- Y is CH(OR*) 2 wherein R* is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl; and (b) deprotecting the cross-coupled compound formed in step (a) under suitable conditions to form the open-chain compound.
- Cross-coupling step (a) is effected using reagents known in the art which are suited to the purpose. For example, the process may be carried out by hydroborating the pre-acyl component with 9-BBN.
- the resulting mixed borane may then be cross-coupled with an organometallic catalyst such as PdCI 2 (dppf) 2 , or any known equivalent thereof, in the presence of such ancillary reagents as cesium carbonate and triphenylarsine.
- Deprotecting step (b) can be carried out with a mild acid catalyst such as p-tosic acid, and typically in a mixed aqueous organic solvent system, such as dioxane-water.
- the open-chain compound can be cyclized using any of a variety of non-nucleophilic bases, such as potassium hexamethyldisilazide or lithium diethyamide.
- the subject invention also provides a method of preparing an epothilone having the structure:
- R ' and R" are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, under suitable conditions to form a deprotected cyclized compound and oxidizing the deprotected cyclized compound under suitable conditions to form a desoxyepothilone having the structure:
- step (b) epoxidizing the desoxyepothilone formed in step (a) under suitable conditions to form the epothilone.
- Deprotecting step (a) is effected using a sequence of treatments comprising a catalyst such as HF-pyridine, followed by t-butyldimethylsilyl triflate in the presence of a base such as lutidine. Dess-Martin oxidation and further deprotection with a catalyst such as HF- pyridine provides the desoxyepothilone.
- the latter compound can then be epoxidized in step (b) using any of a variety of epoxidizing agents, such acetic peracid, hydrogen peroxide, perbenzoic acid, m-chloroperbenzoic acid, but preferably with dimethyldioxirane, in an inert organic solvent such as dichloromethane.
- epoxidizing agents such as acetic peracid, hydrogen peroxide, perbenzoic acid, m-chloroperbenzoic acid, but preferably with dimethyldioxirane, in an inert organic solvent such as dichloromethane.
- the subject invention further provides a method of preparing an epothilone precursor having the structure:
- R is hydrogen or methyl; wherein X is O, or a hydrogen and OR ' ' , each singly bonded to carbon; and wherein R 0 , R ' and R " are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises (a) coupling a compound having the structure: wherein R is an acetyl, with an aldehyde having the structure:
- Y is oxygen, under suitable conditions to form an aldol intermediate and optionally protecting the aldol intermediate under suitable conditions to form an acyclic epthilone precursor having the structure:
- step (b) subjecting the acylic epothilone precursor to conditions leading to intramolecular olefin metathesis to form the epothilone precursor.
- the conditions leading to intramolecular olefin metathesis require the presence of an organometallic catalyst.
- the catalyst contains Ru or Mo.
- the coupling step (a) may be effected using a nonnucleophilic base such as lithium diethylamide or lithium diisopropylamide at subambient temperatures, but preferably at about -78°C.
- the olefin metathesis in step (b) may be carried out using any catalyst known in the art suited for the purpose, though preferably using one of Grubbs's catalysts.
- the present invention provides a compound useful as an intermediate for preparing epothilones having the structure:
- R ' and R " are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR*) 2 , (SR*) 2 , -(O- (CH 2 ) n -0)-, -(0-(CH 2 ) n -S)- or -(S-(CH 2 ) n -S)-; wherein R* is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; wherein R 2 B is a linear, branched or cyclic boranyl moiety; and wherein n is 2, 3 or 4.
- the invention provides the compound wherein R' is T
- the invention also provides the compound having the structure:
- R ' and R ' ' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR) 2 , (SR) 2 , -(O- (CH 2 ) n -0)-, -(0-(CH 2 ) n -S)- or -(S-(CH 2 ) n -S)-; and wherein n is 2, 3 or 4.
- the invention provides the compound wherein R' is TBS, R" is TPS and X is (OMe) 2 .
- the invention further provides a desmethylepothilone analogoue having the structure: wherein R is H or methyl.
- the invention provides a compound having the structure:
- the invention also provides a trans-desmethyldeoxyepothilone analogue having the structure:
- R is H or methyl
- the invention also provides a trans-epothilone having the structure:
- R is H or methyl
- the invention also provides a compound having the structure:
- R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl;
- R' is hydrogen, methyl, ethyl, n-propyl, n-hexyl, , C0 2 Et or (CH 2 ) 3 OTBDPS. and X is a halogen.
- the invention provides the compound wherein R is acetyl and X is iodine.
- the invention additionally provides a method of preparing an open-chain aldehyde having the structure:
- R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein R ' and R ' ' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
- X is a halogen, with a terminal borane having the structure:
- R * 2 B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; and wherein Y is (OR 0 ) 2 , (SR 0 ) 2 , -(0-(CH 2 ) n -0)-, -(0-(CH 2 ) n -S)- or -(S-(CH 2 ) n -S)- where R 0 is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; and wherein n is 2, 3 or 4, under suitable conditions to form a cross-coupled compound having the structure:
- step (b) deprotecting the cross-coupled compound formed in step (a) under suitable conditions to form the open-chain aldehyde.
- the invention provides the method wherein R is acetyl; R' is TBS; R" is TPS; R* 2 B is derived from 9-BBN; and Y is (OMe) 2 .
- Cross-coupling step (a) is effected using reagents known in the art which are suited to the purpose.
- the mixed borane may be cross-coupled with an organometallic catalyst such as PdCI 2 (dppf) 2 , or any known equivalent thereof, in the presence of such reagents as cesium carbonate and triphenylarsme.
- Deprotecting step (b) can be carried out using a mild acid catalyst such as p-tosic acid, typically in a mixed aqueous organic solvent system, such as dioxane-water.
- the invention also provides a method of preparing a protected epothilone having the structure:
- R' and R' ' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkyl-arylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises: (a) monoprotecting a cyclic diol having the structure:
- step (b) oxidizing the cyclic alcohol formed in step (a) under suitable conditions to form the protected epothilone.
- the invention provides the method wherein R' and R" are TBS.
- the monoprotecting step (a) may be effected using any of a variety of suitable reagents, including TBSOTf in the presence of a base in an inert organic solvent.
- the base may be a non-nucleophilic base such as 2,6-lutidine, and the solvent may be dichloromethane.
- the reaction is conducted at subambient temperatures, preferably in the range of -30°C.
- the oxidizing step (b) utilizes a selective oxidant such as Dess-Martin periodinane in an inert organic solvent such as dichloromethane.
- a selective oxidant such as Dess-Martin periodinane in an inert organic solvent such as dichloromethane.
- the oxidation is carried out at ambient temperatures, preferably at 20-25 °C.
- the invention further provides a method of preparing an epothilone having the structure:
- R' and R ' ' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, under suitable conditions to form a desoxyepothilone having the structure:
- step (a) provides the method wherein R' and R" are TBS.
- Deprotecting step (a) is carried out by means of a treatment comprising a reagent such as HF-pyridine.
- the deprotected compound can be epoxidized in step (b) using an epoxidizing agent such acetic peracid, hydrogen peroxide, perbenzoic acid, inch loroperbenzoic acid, but preferably with dimethyldioxirane, in an inert organic solvent such as dichloromethane.
- the invention also provides a method of preparing a cyclic diol having the structure:
- R ' is a hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
- R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein R " is a hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl under suitable conditions to form an enantiomeric mixture of a protected cyclic alcohol having the structure:
- said mixture comprising an ⁇ - and a ⁇ -alcohol component
- step (b) optionally isolating and oxidizing the ⁇ -alcohol formed in step (a) under suitable conditions to form a ketone and thereafter reducing the ketone under suitable conditions to form an enantiomeric mixture of the protected cyclic alcohol comprising substantially the ⁇ - alcohol;
- step (c) treating the protected cyclic alcohol formed in step (a) or (b) with a deprotecting agent under suitable conditions to form the cyclic diol.
- the invention provides the method wherein R' is TBS and R" is TPS.
- Cyclizing step (a) is performed using any of a variety of mild nonnucleophilic bases such as KHMDS in an inert solvent such as THF. The reaction is carried out at subambient temperatures, preferably between -90°C and - 50°C, more preferably at -78°C. Isolation of the unnatural alpha-OH diastereomer is effected by any purification method, including any suitable type of chromatography or by crystallization.
- Chromatographic techniques useful for the purpose include high pressure liquid chromatography, countercurrent chromatography or flash chromatography.
- Various column media are suited, including, inter alia, silica or reverse phase support.
- the beta-OH derivative is then oxidized using a selective oxidant, such as Dess-Martin periodinane.
- the resulting ketone is the reduced using a selective reductant.
- a selective oxidant such as Dess-Martin periodinane.
- a preferred reducing agent is sodium borohydride.
- Treating step (c ) may be effected using a variety of deprotecting agents, including HF- pyridine.
- the invention provides a method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of any of the analogues related to epothilone B disclosed herein optionally in combination with a pharmaceutically suitable carrier.
- the method may be applied where the cancer is a solid tumor or leukemia.
- the method is applicable where the cancer is breast cancer or melanoma.
- the subject invention also provides a pharmaceutical composition for treating cancer comprising any of the analogues of epothilone disclosed hereinabove, as an active ingredient, optionally though typically in combination with a pharmaceutically suitable carrier.
- a pharmaceutical composition for treating cancer comprising any of the analogues of epothilone disclosed hereinabove, as an active ingredient, optionally though typically in combination with a pharmaceutically suitable carrier.
- the pharmaceutical compositions of the present invention may further comprise other therapeutically active ingredients.
- the subject invention further provides a method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of any of the analogues of epothilone disclosed hereinabove and a pharmaceutically suitable carrier.
- the method is especially useful where the cancer is a solid tumor or leukemia.
- the compounds taught above which are related to epothilones A and B are useful in the treatment of cancer, and particularly, in cases where multidrug resistance is present, both in vivo and in vitro.
- the ability of these compounds as non-substrates of MDR in cells shows that the compounds are useful to treat, prevent or ameliorate cancer in subjects suffering therefrom.
- the magnitude of the therapeutic dose of the compounds of the invention will vary with the nature and severity of the condition to be treated and with the particular compound and its route of administration.
- the daily dose range for anticancer activity lies in the range of 0.001 to 25 mg/kg of body weight in a mammal, preferably 0.001 to 10 mg/kg, and most preferably 0.001 to 1.0 mg/kg, in single or multiple doses. In unusual cases, it may be necessary to administer doses above 25 mg/kg.
- Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a compound disclosed herein.
- oral, rectal, topical, parenteral, ocular, pulmonary, nasal, etc. routes may be employed.
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, etc.
- compositions include compositions suitable for oral, rectal, topical (including transdermal devices, aerosols, creams, ointments, lotions and dusting powders), parenteral (including subcutaneous, intramuscular and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation) or nasal administration.
- topical including transdermal devices, aerosols, creams, ointments, lotions and dusting powders
- parenteral including subcutaneous, intramuscular and intravenous
- ocular ophthalmic
- pulmonary nasal or buccal inhalation
- any of the unusual pharmaceutical media may be used, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (e.g., suspensions, elixers and solutions); or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc., in the case of oral solid preparations are preferred over liquid oral preparations such as powders, capsules and tablets. If desired, capsules may be coated by standard aqueous or non-aqueous techniques.
- the compounds of the invention may be administered by controlled release means and devices.
- compositions of the present invention suitable for oral administration may be prepared as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient in powder or granular form or as a solution or suspension in an aqueous or nonaqueous liquid or in an oil-in-water or water-in- oil emulsion.
- Such compositions may be prepared by any of the methods known in the art of pharmacy.
- compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers, finely divided solid carriers, or both and then, if necessary, shaping the product into the desired form.
- a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granule optionally mixed with a binder, lubricant, inert diluent or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- THP lvcidol 13: A solution of (R)-( + )-glycidol 12 (20 g; 270 mmol) and freshly distilled 3,4- dihydro-2H-pyran (68.1 g; 810 mmol) in CH 2 CI 2 (900 ml) was treated with pyridinium p- toluenesulfonate (2.1 g; 8.36 mmol) at rt and the resulting solution was stirred for 16 h. Approximately 50% of the solvent was then removed in vacuo and the remaining solution was diluted with ether (1 L).
- EXAMPLE 3 MOM ether 13b A solution of alcohol 13a (24 g; 88.9 mmol) and N, ⁇ /-diisopropylethylamine (108 ml; 622 mmol) in anhydrous 1 ,2-dichloroethane (600 ml) was treated with chloromethyl methyl ether (17 ml; 196 mmol), and the resulting mixture was heated to 55 °C for 28 h. The dark mixture was then cooled to rt and treated with saturated aqueous sodium bicarbonate solution (300 ml). The layers were separated, and the organic layer was washed successively with saturated aqueous sodium bicarbonate solution (200 ml) and brine (200 ml).
- Alcohol 14 A solution of THP ether 13b (20 g; 63.7 mmol) in methanol (90 ml) was treated with pyridinium p-toluenesulfonate (4.0 g; 15.9 mmol) and the resulting mixture was stirred at rt for 16 h. The reaction was then quenched by the addition of saturated aqueous sodium bicarbonate solution (100 ml), and the excess methanol was removed in vacuo. The residue was diluted with ether (300 ml), and the organic layer was washed successively with saturated aqueous sodium bicarbonate solution (200 ml) and brine (200 ml). The organic layer was dried (MgS0 4 ), filtered, and concentrated. Purification of the residue by flash chromatography (silica, 40 - » 50% ether: hexanes) provided alcohol 14 (13.1 g; 95%) as a colorless oil.
- Ketone 15 A solution of alcohol 14 (1.0 g; 4.35 mmol), 4 A mol. sieves, and N- methylmorpholine-N-oxide (1.0 g; 8.7 mmol) in CH 2 CI 2 (20 ml) at rt was treated with a catalytic amount of tetra-n-propylammonium perruthenate, and the resulting black suspension was stirred for 3 h. The reaction mixture was then filtered through a pad of silica gel (ether rinse), and the filtrate was concentrated in vacuo. Purification of the residue by flash chromatography (silica, 10% ethe ⁇ hexanes) afforded ketone 15 (924 mg; 93%) as a light yellow oil.
- EXAMPLE 20 Hvdrolvsis of dimethyl acetal 21; The acetate 20 (0.610 g, 0.770 mmol) was dissolved in dioxane/H 2 0 (9:1, 15 mL) and -TSA ⁇ 2 0 (0.442 g, 2.32 mmol) was added. The mixture was then heated to 55°C. After 3 h, the mixture was cooled to rt and poured into Et 2 0. This solution was washed once with sat NaHC0 3 (30 mL), once with brine (30 mL) and dried over anhydrous MgS0 4 .
- Lactone 22 (32 mg, 0.0376 mmol) was treated with 1ml of pyridine buffered HF-pyridine - THF solution at room temperture for 2 h. The reaction mixure was poured into saturated aqueous NaHC0 3 and extracted with ether . The organic layer was washed in sequence with saturated CuSO 4 (10 ml x 3) and saturated NaHCO 3 (10 ml), then dried over Na 2 S0 4 and concentrated under vacuum. The residue was purified by flash chromatography (silica, 25% EtOAc in hexane) and to give diol 22a (22 mg, 99%) as white foam.
- TBS-protection To a cooled (-30°C) solution of diol 22a (29 mg, 0.0489 mmol) and 2,6- lutidine (0.017 ml, 0.147 mmol) in anhydrous CH 2 CI 2 (1ml) was added TBSOTf (0.015 ml, 0.0646 mmol). The resulting solution was then stirred at -30°C for 30 min. The reaction was quenched with 0.5M HCI (10 ml) and extracted with ether (15 ml). Ether layer was washed with saturated NaHC0 3 , dried (Na 2 S0 4) and concentrated in vacuo. Purifiction of the residue by flash chromatogrphy (silica, 8% EtOAc in hexane) afforded TBS ether 22B (32 mg, 93%) as white foam.
- Epothilone To a cooled (-50°C) solution of desoxyepothilone (9 mg, 0.0189 mmol) in dry CH 2 CI 2 (1 ml) was added freshly prepared dimethyldioxirane (0.95 ml, 0.1 M in acetone). The resulting solution was allowed to warm up to -30°C for 2 h. A stream of nitrogen was then bubbled through the solution to remove excess DMDO. The residue was purified by flash chromatography (silica , 40% EtOAc in hexane) and afforded epothilone A (4.6 mg, 49%) as colorless solid and 0.1 mg of cis-epoxide diastereomer. This material was identical with the natural epothilone A in all respects.
- Alcohol 2A A mixture of (S)-(-)-1,1 (259 mg. 0.91 mmoL), Ti(0-i-
- Pr) 4 (261 //L;0.90 mmol), and 4 A sieves (3.23g) in CH 2 C1 2 (16 mL) was heated at reflux for 1 h. The mixture was cooled to rt and aldehyde 1 was added. After 10 min. the suspension was cooled to -78°C, and allyl tributyltin (3.6 mL; 1 1.60 mmol) was added. The reaction mixture was stirred for 10 min at -78 °C and then placed in a -20 °C freezer for 70 h.
- EXAMPLE 31 lodoolefin acetate 8C To a suspension of ethyltriphenylphosphonium iodide (1.125 g, 2.69 mmol) in THF (10 mL) was added nBuLi (2.5 M soln in hexanes, 1.05 mL, 2.62 mmol) at rt. After disappearance of the solid material, the solution was added to a mixture of iodine (0.613 g, 2.41 mmol) in THF (20 mL) at -78 °C.
- the resulting suspension was vigorously stirred for 5 min at -78 °C, then warmed up -20 °C, and treated with sodium hexamethyldisilazane (1 M soln in THF, 2.4 mL, 2.4 mmol).
- the resulting red solution was stirred for 5 min followed by the slow addition of aldehyde 9C (0.339 g, 1.34 mmol).
- the mixture was stirred at -20 °C for 40 min, diluted with pentane (50 mL), filtered through a pad of celite, and concentrated.
- EXAMPLE 32 Acetal 13C: To a solution of olefin "7C" (0.082 g, 0.13 mmol) in THF (0.5 mL) was added 9- BBN (0.5 M soln in THF, 0.4 mL, 0.2 mmol). After stirring at rt. for 3.5 h, an additional portion of 9-BBN (0.5 M soln in THF, 0.26 mL, 0.13 mmol) was added. In a separate flask, iodide 8C (0.063 g, 0.16 mmol) was dissolved in DMF (0.5 mL).
- EXAMPLE 34 Macrocycle 15C-(5ft): To a solution of aldehyde 14C (0.021 g, 0.024 mmol) in THF (5 mL) at -78 °C was added KHMDS (0.5 M soln in toluene, 0.145 mL, 0.073 mmol). The solution was stirred at -78 °C for 1 h, then quenched with sat'd NH 4 CI, and extracted with ether (3 x 15 mL). The combined organic layers were dried with MgS0 4 , filtered, and concentrated.
- KHMDS 0.5 M soln in toluene, 0.145 mL, 0.073 mmol
- Alcohol 15C To a solution of diol 15C" (0.0066 g, 0.01 1 mmol) in 0.5 mL of CH 2 CI 2 at - 78 °C was added 2,6-lutidine ⁇ 7 ⁇ l, 0.060 mmol) and TBSOTf (5 ⁇ l, 0.022 mmol). The resulting solution was stirred at -30 °C for 0.5 h, then quenched with H 2 0 (5 mL), and extracted with Et 2 0 (4 x 10 mL). The ether solutions were washed with 0.5 M HCI (1 x 10 mL), sat'd NaHC0 3 (1 x 10 mL), dried over MgS0 4 , filtered, and concentrated. Flash column chromatography (hexanes/ethyl acetate, 93:7) gave 0.0070 g (89%) of the alcohol 15C" as a pale yellow oil.
- Epothilone B (2) To a solution of desoxyepothilone B (0.0022 g, 0.0041 mmol) in CH 2 CI 2
- EXAMPLE 41 8-Desmethylepothilone A Crotylation product: To a stirred mixture of potassium tert-butoxide (1.0 M soln in THF, 50.4 mL, 50.4 mmol), THF (14 mL), and c/ ' s-2-butene (9.0 mL, 101 mmol) at -78°C was added n- BuLi (1.6 M, in hexanes, 31.5 mL, 50.4 mmol). After complete addition of n-BuLi, the mixture was stirred at -45°C for 10 min and then cooled to -78°C.
- n-BuLi 1.6 M, in hexanes, 31.5 mL, 50.4 mmol
- the reaction was treated with 3N NaOH (36.6 mL, 110 mmol) and 30% H 2 0 2 (15 mL) and the solution brought to reflux for 1 h.
- the reaction was poured into Et 2 0 (300 mL) and washed with H 2 0 (100 mL), brine (30 mL) and dried over anhydrous MgS0 4 .
- the crude material was placed in a bulb-to-bulb distillation apparatus to remove the ligand from the desired product. Heating at 80°C at 2 mm Hg removed 90% of the lower boiling ligand.
- TBS ether 5D Alcohol 4D (5.00 g, 21.4 mmol) was dissolved in CH 2 CI 2 (150 mL) and 2,6- lutidine (9.97 mL, 85.6 mmol) was added. The mixture was cooled to 0°C and TBSOTf (9.83 mL, 42.8 mmol) was slowly added. The reaction was then warmed to rt. After 1 h, the reaction was poured into Et 2 0 (300 mL) and washed once with 1 N HCI (50 mL), once with sat NaHC0 3 (50 mL), once with brine (30 mL) and dried over anhydrous MgS0 4 .
- Aldehyde 6D The olefin 5 (4.00 g, 1 1 .49 mmol) was dissolved in 1 :1 MeOH/CH 2 CI 2 (100 mL). Pyridine (4.0 mL) was then added and the mixture cooled to -78°C. Ozone was then bubbled through the reaction for 10 minutes before the color turned light blue in color. Oxygen was then bubbled through the reaction for 10 min. Dimethyl sulfide (4.0 mL) was then added and the reaction slowly warmed to rt. The reaction was stirred overnight and then the volatiles were removed in vacuo.
- EXAMPLE 44 Dianion addition product 7D: The tert-butyl isobutyrylacetate (0.653 g, 3.51 mmol) was added to a suspension of NaH (60% in mineral oil, 0.188 g, 4.69 mmol) in THF (50 mL) at rt. After 10 min, the mixture was cooled to 0°C. After an additional 10 min, n-BuLi (1.6 M in hexanes, 2.20 mL, 3.52 mmol) was slowly added. After 30 min, the aldehyde 6D (1.03 g,
- EXAMPLE 45 Directed reduction: To a solution of tetramethylammonium triacetoxyborohydride (1.54 g, 5.88 mmol) in acetonitrile (4.0 mL) was added anhydrous AcOH (4.0 mL). The mixture was stirred at rt for 30 min before cooling to -10°C. A solution of the ester 7D (0.200 g, 0.39 mmol) in acetonitrile (1.0 mL) was added to the reaction and it was stirred at -10°C for 20 h. The reaction was quenched with 1 N sodium-potassium tartrate (10 mL) and stirred at rt for 10 min.
- EXAMPLE 48 Debenzylation: The ketone (benzyl ether) (1.85 g, 2.87 mmol) was dissolved in EtOH (50 mL), and Pd(OH) 2 (0.5 g) was added. The mixture was then stirred under an atmosphere of H 2 . After 3 h, the reaction was purged with N 2 and then filtered through a pad of celite rinsing with CHCI 3 (100 mL). Purification by flash chromatography on silica gel eluting with ethyl acetate in hexanes (12% - 15%) gave 1.43 g (90%) of the diastereomeric alcohols as a clear oil. The C3 diastereomers were separated by flash chromatography on TLC-grade Si0 2 eluting with ethyl acetate in hexanes (15%):
- TBS ester 10D The olefin 9D (0.420 g, 0.76 mmol) was dissolved in CH 2 CI 2 (15 mL) and treated successively with 2,6-lutidine (1.33 mL, 11.4 mmol) and TBSOTf (1.32 mL, 5.73 mmol). After 7 h, the reaction was poured into Et 2 0 (100 mL) and washed successively with 0.2N HCI (25 mL), brine (20 mL) and dried over anhydrous MgS0 4 .
- Epoxide formation Diol 16D (0.008 g, 0.017 mmol) was dissolved in CH 2 CI 2 (1.0 mL) and cooled to -60°C Dimethyldioxirane (0.06 M, 0.570 mL, 0.0034 mmol) was then slowly added. The reaction temperature was slowly warmed to -25°C. After 2 h at -25°C, the volatiles were removed from the reaction at -25°C under vacuum.
- Carbons 9 through 11 insulate domains of chirality embracing carbons 3 through 8 on the acyl side of the macrolactone, and carbons 12 through 15 on the alkyl side.
- the hydropyran platforms service various stereospecific reactions (see formalism 7A ⁇ 8A) Furthermore, the products of these reactions are amenable to ring opening schemes, resulting in the expression of acycnc fragments with defined stereochemical relationships (cf. 8A - 9A).
- the present invention provides the application of two such routes for the synthesis of compound 4A.
- Route 1 which does not per se involve control of the issue of absolute configuration, commences with the known aldehyde 10A. Shafiee, A., et al., ) Heterocyclic Chem., 1979, 76, 1563; Schafiee, A.; Shahocini, S. J.
- carbinol 14A was subjected to lipase 30, in the presence of isopropenyl acetate, following the prescriptions of Wong (Hsu, S.-H., et al., Tetrahedron Lett., 1990, 31 , 6403)to provide acetate 15A in addition to the enantiomerically related free glycal 16A.
- Compound 15A was further advanced to the PMB protected system 17A.
- reaction of 17A with dimethyldioxirane (Danishefsky, S.J.; Bilodeau, M.T. Angew. Chem. Int. Ed. Engl., 1996, 35, 1381 ) generated an intermediate (presumably the corresponding glycal epoxide) which, upon treatment with sodium metaperiodate gave rise to aldehyde formate 18A. Allylation of 18A resulted in the formation of carbinol 19A in which the formate ester had nicely survived. (For a review of allylations, see: Yamamoto, Y.; Asao, N. Chem. Rev.
- system 3B One of the interesting features of system 3B is the presence of geminal methyl groups at carbon 4 (epothilone numbering). Again, use is made of a dihydropyran strategy to assemble a cyclic matrix corresponding, after appropriate disassembly, to a viable equivalent of system 3B. The expectation was to enlarge upon the dihydropyran paradigm to include the synthesis of gem- dimethyl containing cyclic and acyclic fragments. The particular reaction type for this purpose is generalized under the heading of transformation of 4B - 5B (see Figure 7). Commitment as to the nature of the electrophile E is avoided. Accordingly, the question whether a reduction would or would not be necessary in going from structure type 5B to reach the intended generalized target 3B is not addressed.
- the opening step consisted of a stereochemical ly tuneable version of the diene- aldehyde cyclocondensation reaction (Figure 8; Danishefsky, S.J., Aldrichimica Acta, 1986, 79, 59), in this instance drawing upon chelation control in the merger of the readily available enantiomerically homogenous aldehyde 6B with the previously known diene 7B.
- Figure 8 Danishefsky, S.J., et al., ).
- olefin metathesis is therefore amenable to the challenge of constructing the sixteen membered ring containing both the required epoxy and thiazolyl functions of the target system. It is pointed out that no successful olefin metathesis reaction has yet been realized from seco-systems bearing a full compliment of functionality required to reach epothilone. These negative outcomes may merely reflect a failure to identify a suitable functional group constraint pattern appropriate for macrocylization.
- the Total Synthesis of Epothilone B Extension of the Suzuki Coupling Method
- the present invention provides the first total synthesis of epothilone A (1). D.
- Important preparative features of the present method include the enantioselective synthesis of the t ⁇ substituted vinyl iodide 8C, the palladium-mediated stereospecific coupling of compounds 7C and 8C to produce compound 13C (a virtually unprecedented reaction in this form), and the amenability of Z-desoxyepothilone B (2C) to undergo regio- and stereoselective epoxidation under approp ⁇ ate conditions.
- TaxolTM (pac taxel) is a clinically proven drug, its formulation continues to be difficult. In addition, taxol induces the multidrug resistance (MDR) phenotype. Hence, any novel agent that has the same mechanism of action as taxol and has the prospect of having superior therapeutic activity warrants serious study Bollag, D. M , et al , Cancer Res. 1995, 55, 2325.
- the present invention provides epothilone analogs that are more effective and more readily synthesized than epothilone A or B.
- the syntheses of the natural products provide ample material for preliminary biological evaluation, but not for producing adequate amounts for full development.
- One particular area where a structural change could bring significant relief from the complexities of the synthesis would be in the deletion of the C8 methyl group from the polypropionate domain (see target system 3D).
- the need to deal with this C8 chiral center complicates all of the syntheses of epothilone disclosed thus far. Deletion of the C8 methyl group prompts a major change in synthetic strategy related to an earlier diene-aldehyde cyclocondensation route.
- MTP Microtubule protein
- assembly buffer containing 0.1 M MES (2-(N-morpholino) ethanesulfonic acid), 1 mM EGTA, 0.5 mM MgCI 2 , 1 mM GTP and 3M glycerol, pH 6.6.
- concentration of tubulin in MTP was estimated to be about 85%.
- cytotoxicities of test compounds were determined by the growth of human lymphoblastic leukemic cells CCRF-CEM, or their sublines resistant to vinblastine and taxol (CCRF-CEM/VBL) or resistant to etoposide (CCRF-CEM/VM-1 ). XTT-microculture tetrazolium/formazan assays were used. b The IC 50 values were calculated from 5-6 concentrations based on the median-effect plot using computer software.
- model system I is desoxyepothilone.
- Model system 2 has the structure:
- Model system 3 has the structure:
- (B)/(A) or (C)/(A) ratio > 1 indicates fold of resistance when compared with the parent cell line.
- b. (B)/(A) or (C)/(A) ratio ⁇ 1 indicates fold of collateral sensitivity when compared with the parent cell line.
- CCRF-CEM is the parent cell line.
- CCRF-CEM/VBL MDR cell line
- CCRF-CEMA/M Topo II mutated cell line
- CCRF-CEM/VM cells are collaterally sensitive to certain epothilone compounds.
- DC-3F Actinomycin D > Vinblastine ⁇ Epothilone A (0.0036 ⁇ M) > Desoxy epothilone >VP-16> Taxol (0.09 ⁇ M) > Model system I and triol analog
- DC-3F/ADX Desoxyepothilone ⁇ Epothilone A (0.06 ⁇ M) > Actinomycin D
- DC-3F/ADX cells (8379-fold resistant to actinomycin D) are > 338 fold (ca. 8379 fold) resistant to Taxol, VP-16, Vinblastine and Actinomycin D but ⁇ 20 fold resistant to epothilone compounds.
- Drug A EPOTHILONE B (#8) ( ⁇ M)
- Drug B TAXOL ( ⁇ M)
- Drug C VINBLASTINE ( ⁇ M)
- Epothilone B and Taxol have a similar mechanism of action (polymerization) but Epothilone B synergizes VBL whereas Taxol antagonizes VBL.
- Number of asterisks denotes relative potency.
- ⁇ Number in parentheses indicates relative resistance (fold) when compared with parent cell line.
- Epo B 0.7 4 24.7 -0.1 -0.7 -1.4 + 0.3 1.0 0.53 0.48 0.46 1.0 5 25.0 + 0.1 -1.5 -2.4 + 0.1 1.0 0.46 0.35 0.43
- Epo B 0.7 25.8 + 0.1 -0.7 -1 .0 -0.2 1.0 0.32 0.40 0.33 1.0 6 26.0 -0.2 -1.3 -2.1 -0.5 1.0 0.41 0.27 0.31
- Epo B Epo B, epothilone B; VBL, vinblastine.
- the tumor volumes for each group on day 7 was about 1 mm 3 .
- the average volumes of CCRF-CEM control group on day 12, 17 and 22 were 19, 7 and 171 mm 3 , and of CCRF-CEM/VBL control group were 35, 107 and 278 mm 3 , respectively.
- mice died of drug toxicity on day 18, 19 and 21.
- epothilones and taxol have similar modes of action by stabilizing polymerization of microtubules.
- epothilones and taxol have distinct novel chemical structures.
- MDR cells are 1500-fold more resistant to taxol (CCRF-CEM/VBL cells), epothilone A showed only 8-fold resistance and epothilone B showed only 5-fold resistance.
- CCRF-CEM cells For CCRF-CEM cells,
- Epo B is 6-fold more potent than Epo A and 10-fold more potent than Taxol.
- Desoxyepothilone B and compd #24 are only 3-4-fold less potent than Taxol and compound #27 is > 2-fold more potent than
- Taxol Finally, Taxol and vinblastine showed antagonism against CCRF-CEM tumor cells, whereas the combination of Epo B + vinblastine showed synergism.
- Epo B (0.0021 ; 1/6* [1]* *) > #27 (0.0072; 1/20.6) > #1 (0.012, 1/34.3) > #10 (0.01 7, 1/48.6) >
- Epo A (0.020, 1/57.1 [1/9.5]) > #6 (0.035) > #20 (0.049) > #24 (0.053) > #25 (0.077) > #22 (0.146) > #26 (0.197) > #1 7 (0.254) > #1 1 (0.262) > VBL (0.332, 1/948.6 [1/158.1]) > Taxol (4.14;
- MX-1 tissue 100 ⁇ l/mouse was implanted s.c on day 0. Every other day i.p. treatments were given on day 8, 10, 12, 14 and 16. The average tumor volume of control group on day 10, 12, 14, 16 and 18 were 78, 151 , 372, 739 and 1257 mm 3 , respectively.
- Epothilone B 0.4 QDx6 b 27.1 -0.2 -0.6 -1.1 -3.4 -3.9 1.08 1.07 1.27 1.07 1/8 0.8 QDx5 c 27.0 0 -0.8 -3.1 -4.7 -4.7 0.57 0.89 0.46 0.21 5/8
- Taxol 4 QDx8 26.7 + 0.1 + 0.2 + 0.3 + 0.4 + 0.8 0.62 0.39 0.56 0.51 0/8 6.5 QDx8 26.7 + 0.1 + 0.3 + 0.3 + 0.4 + 1.7 0.19 0.43 0.20 0.54 0/8
- mice in each group Control, 15; Epothilone B, 8; Desoxythilone B, 5 and Taxol, 8. The average tumor volume of control group on day 5, 7, 9 and 11 were 16, 138, 436 and 1207 mm 3 , respectively. See Figs. 44(a) and (b).
- One moribund mouse was sacrificed for toxicological examinations on day 11.
- Epothilone B 0.3 26.9 + 0.5 + 0.4 -0.3 -1.2 1.00 0.71 0.71 0.84 0/7 died 0.6 C 27.4 -0.3 -1.3 -2.1 -2.1 1.08 0.73 0.81 0.74 3/7 died
- MX-1 tissue 50 ⁇ l/mouse was implanted s.c. on day 0. Every other day i.p. treatments were given on day 7, 9, 11, 13 and 15.
- mice in each group Control, 8; Desoxyepothilone B, 6; Epothilone B, 7; Taxol, 7 and Vinblastine, 7.
- the average tumor volume of control group on day 1 1, 13, 15 and 17 were 386, 915, 1390 and 1903 mm 3 , respectively. See Fig. 45. b. One out of six mice with no detectable tumor on day 35. c. Three mice died of drug toxicity on day 17. Every other day i.p. treatments were given except day 15. d. Four mice died of drug toxicity on day 13, 13, 13, 15. e. One mouse died of drug toxicity on day 15.
- Minced MX-1 tumor tissue 50 ⁇ l/mouse was implanted s.c. on day 0.
- All assays were determined on day 30; averaged values were given.
- Desoxyepothilone B 25 mg/kg was given i.p on day 7, 9, 11, 13, 15; 35mg/kg on day 17, 19, 23, 24, 25.
- Taxol 5mg/kg was given i.p. on day 7, 9, 11 , 13, 15; 6mg/kg on day 17, 19, 23, 24, 25. e.
- DesoxyEpoB 35 25.0 + 0.3 + 0.7 + 0.6 + 0.8 0.31 0.27 0.30 0.34 0/8
- Taxol 6 25.3 + 1.7 + 1.8 + 0.8 + 0.9 0.57 0.66 085 0.90 0/8
- Camptothecin 1.5 24.4 + 1.1 + 0.9 + 1.7 + 1.4 1.08 0.72 0.61 0.72 0/8 3.0 24.5 -0.6 -0.4 -0.8 -0.9 0.95 0.76 0.61 0.43 0/6
- MCF-7/Adr cell 3 x 10 6 /mouse was implanted s.c. on day 0. Every other day i.p. treatments were given on day 8, 10, 12, 14 and 16. The average tumor volume of control group on day 11 , 13, 15 and 17 were 392, 919, 1499 and 2372mm 3 , respectively.
- desoxyepothilone B performs significantly better than taxol, vinblastine, adriamycin and camptothecin against MDR tumor xenografts (human mammary adeoncarcinoma MCF-7/Adr xenografts).
- MDR tumor xenografts human mammary adeoncarcinoma MCF-7/Adr xenografts.
- This drug-resistant tumor grows very aggressively and is refractory to taxol and adriamycin at half their lethal doses.
- Taxol at 6mg/kg i.p. Q2Dx5 reduced tumor size only 10% while adriamycin resulted in only a 22% reduction on day 17.
- desoxyepothilone B at 35 mg/kg reduced tumor size by 66% on day 17 and yet showed no reduction in body weight or apparent toxicity. Even at the LD 50 dosage for taxol (12mg/kg) or adriamycin (3mg/kg), desoxyepothilone B still performed more effectively. By comparison, camptothecin at 1.5 and 3.0 mg/kg reduced tumor size by 28% and 57%, respectively. Overall, in comparison with the four important anticancer drugs in current use, i.e., taxol, adriamycin, vinblastine and camptothecin, desoxyepothilone B showed superior chemotherapeutic effect against MDR xenografts.
- Epothilone B a 0.6QDx4
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69734362T DE69734362T2 (en) | 1996-12-03 | 1997-12-03 | SYNTHESIS OF EPOTHILONES, INTERMEDIATE PRODUCTS, ANALOGUES AND USES THEREOF |
JP50109599A JP4579351B2 (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilone and its intermediates and analogs and uses thereof |
CA2273083A CA2273083C (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP97954055A EP0977563B1 (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
AU57929/98A AU756699B2 (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US10/329,090 US6965034B2 (en) | 1996-12-03 | 2002-12-23 | Synthesis of epothilones, intermediates thereto and analogues thereof |
US10/401,494 US20040260098A1 (en) | 1996-12-03 | 2003-03-28 | Synthesis of epothilones, intermediates thereto and analogues thereof |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3228296P | 1996-12-03 | 1996-12-03 | |
US60/032,282 | 1996-12-03 | ||
US3376797P | 1997-01-14 | 1997-01-14 | |
US60/033,767 | 1997-01-14 | ||
US4756697P | 1997-05-22 | 1997-05-22 | |
US60/047,566 | 1997-05-22 | ||
US4794197P | 1997-05-29 | 1997-05-29 | |
US60/047,941 | 1997-05-29 | ||
US5553397P | 1997-08-13 | 1997-08-13 | |
US60/055,533 | 1997-08-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999001124A1 WO1999001124A1 (en) | 1999-01-14 |
WO1999001124A9 true WO1999001124A9 (en) | 1999-05-14 |
Family
ID=27534391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/022381 WO1999001124A1 (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (15) | US6242469B1 (en) |
EP (2) | EP1386922B1 (en) |
JP (2) | JP4579351B2 (en) |
AU (1) | AU756699B2 (en) |
CA (1) | CA2273083C (en) |
DE (1) | DE69734362T2 (en) |
TW (1) | TW504511B (en) |
WO (1) | WO1999001124A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41990E1 (en) | 1996-12-03 | 2010-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0873341B1 (en) | 1995-11-17 | 2003-09-10 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone derivatives, preparation and use |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
JP4274583B2 (en) | 1996-11-18 | 2009-06-10 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | Epothilone C, D, E and F, manufacturing and drugs |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
CA2299608A1 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
CA2320182C (en) * | 1998-02-05 | 2008-11-25 | Novartis Ag | Compositions containing organic compounds |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
AU2002300841B2 (en) * | 1998-02-19 | 2006-03-30 | Novartis Ag | Fermentative preparation process for cytostatics and crystal forms thereof |
US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
FR2775187B1 (en) | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
NZ506742A (en) * | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
GB9810659D0 (en) * | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
DE19826988A1 (en) | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
CA2352505C (en) | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
CN1340053A (en) * | 1999-02-11 | 2002-03-13 | 舍林股份公司 | Epothilon derivatives, method for the production and the use as pharmaceuticals |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
EP2308833A3 (en) | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
AU772750C (en) | 1999-04-30 | 2005-02-24 | Schering Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6414015B1 (en) | 2000-01-28 | 2002-07-02 | Utah State University | Laulimalide microtubule stabilizing agents |
US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
IL155306A0 (en) * | 2000-10-13 | 2003-11-23 | Univ Mississippi | Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
EP1353667A1 (en) * | 2001-01-25 | 2003-10-22 | Bristol-Myers Squibb Company | Parenteral formulations containing epothilone analogs |
CA2434526C (en) * | 2001-01-25 | 2011-11-01 | Bristol Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
KR100851719B1 (en) * | 2001-01-25 | 2008-08-11 | 브리스톨-마이어스스퀴브컴파니 | Methods of Administering Epothilone Analogs for The Treatment of Cancer |
EP1385529A4 (en) | 2001-02-20 | 2007-05-09 | Bristol Myers Squibb Co | Treatment of refractory tumors using epothilone derivatives |
RU2003128312A (en) * | 2001-02-20 | 2005-02-10 | Бристол-Маерс Сквибб Компани (Us) | EPOTHYLON DERIVATIVES USED FOR TREATMENT OF RESISTANT TUMORS |
US7312237B2 (en) * | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
US20070203346A1 (en) * | 2001-04-30 | 2007-08-30 | Oregon State University | Method for synthesizing epothilones and epothilone analogs |
JP2004532888A (en) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | Epothilone derivative |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20030176368A1 (en) * | 2001-09-06 | 2003-09-18 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
TW200303202A (en) * | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
AU2003218110A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
US6989131B2 (en) * | 2002-03-12 | 2006-01-24 | Uop Llc | Catalytic reactor with integral evaporator |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
CN101389334A (en) * | 2002-05-20 | 2009-03-18 | 高山生物科学股份有限公司 | Methods to administer epothilone d |
EP2179745A1 (en) * | 2002-06-10 | 2010-04-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2003105828A1 (en) * | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
DE60330407D1 (en) * | 2002-08-23 | 2010-01-14 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereof, analogs and their use |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
RU2462463C2 (en) * | 2002-08-23 | 2012-09-27 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Synthesis of epothiliones, intermediate products thereof, analogues and use thereof |
US7384964B2 (en) * | 2002-08-23 | 2008-06-10 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP2287168B1 (en) | 2002-09-23 | 2013-02-13 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
CA2499682A1 (en) * | 2002-10-09 | 2004-04-22 | Kosan Biosciences, Inc. | Epo d + 5-fu/gemcitabine |
WO2004032923A1 (en) * | 2002-10-11 | 2004-04-22 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
KR20050119665A (en) * | 2003-03-28 | 2005-12-21 | 코산 바이오사이언시즈, 인코포레이티드 | Devices, methods, and compositions to prevent restenosis |
DE10331004A1 (en) * | 2003-07-03 | 2005-02-24 | Schering Ag | Process for the preparation of C1-C15 fragments of epothilones and their derivatives |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
ATE550019T1 (en) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
WO2007015929A2 (en) * | 2005-07-27 | 2007-02-08 | University Of Toledo | Epothilone analogues |
PE20070427A1 (en) * | 2005-08-30 | 2007-04-21 | Novartis Ag | BENZIMIDAZOLES DERIVED COMPOUNDS SUBSTITUTED AS TYROSINE KINASE INHIBITORS |
AU2006287553A1 (en) * | 2005-09-08 | 2007-03-15 | Chromatin, Inc. | Plants modified with mini-chromosomes |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
KR101464385B1 (en) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
BRPI0711591A2 (en) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | iap bir domain binding compound |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
WO2008070672A2 (en) | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
DK2805945T3 (en) | 2007-01-10 | 2019-07-15 | Msd Italia Srl | AMID-SUBSTITUTED INDAZOLS AS POLY (ADP-RIBOSE) POLYMERASE (PARP) REQUESTS |
AU2008212788A1 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
MX2009009304A (en) | 2007-03-01 | 2009-11-18 | Novartis Ag | Pim kinase inhibitors and methods of their use. |
WO2008111855A1 (en) * | 2007-03-14 | 2008-09-18 | The New Zealand Institute For Plant And Food Research Limited | Biosensor, surface coating and assay |
US8435983B2 (en) * | 2007-03-23 | 2013-05-07 | The University Of Toledo | Conformationally restrained epothilone analogues as anti-leukemic agents |
WO2008144062A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
CN104116736A (en) | 2008-04-24 | 2014-10-29 | 百时美施贵宝公司 | Use of epothilone D in treating Tau-associated diseases including Alzheimer's disease |
ES2645692T3 (en) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Rapamycin microcapsules and their use for cancer treatment |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
UA109417C2 (en) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | Substituted piperidines, which improve activity of p53, and use thereof |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
SG181803A1 (en) | 2009-12-17 | 2012-07-30 | Merck Sharp & Dohme | Aminopyrimidines as syk inhibitors |
EP2534170B1 (en) | 2010-02-12 | 2017-04-19 | Pharmascience Inc. | Iap bir domain binding compounds |
US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
KR102072631B1 (en) | 2010-08-17 | 2020-02-03 | 시르나 쎄러퓨틱스 인코퍼레이티드 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
EP2665493B1 (en) | 2011-01-20 | 2018-03-21 | Board Of Regents, The University Of Texas System | Mri markers, delivery and extraction systems, and methods of manufacture and use thereof |
CN103732592A (en) | 2011-04-21 | 2014-04-16 | 默沙东公司 | Insulin-like growth factor-1 receptor inhibitors |
US20140221314A1 (en) | 2011-05-31 | 2014-08-07 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
CN103747804B (en) | 2011-06-10 | 2016-08-17 | 梅尔莎纳医疗公司 | Protein-polymer-drug conjugate |
CN102863474A (en) | 2011-07-09 | 2013-01-09 | 陈小平 | Platinum compounds for treating cell proliferative diseases and preparation method and application thereof |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
CN102993239A (en) | 2011-09-19 | 2013-03-27 | 陈小平 | Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
US9416111B2 (en) | 2012-06-22 | 2016-08-16 | Merck Sharp & Dohme Corp. | Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2014075391A1 (en) | 2012-11-17 | 2014-05-22 | 北京市丰硕维康技术开发有限责任公司 | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
CA2892361A1 (en) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20140206681A1 (en) | 2013-01-23 | 2014-07-24 | Ronald M. Kim | Btk inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
CN105283178A (en) | 2013-06-11 | 2016-01-27 | 拜耳制药股份公司 | Combinations for the treatment of cancer comprising an MPS-1 kinase inhibitor and a mitotic inhibitor |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
KR102355745B1 (en) | 2013-10-11 | 2022-01-26 | 아사나 바이오사이언시스 엘엘씨 | Protein-polymer-drug conjugates |
US9834554B2 (en) | 2013-12-20 | 2017-12-05 | Merck Sharp & Dohme Corp. | BTK inhibitors |
US9637486B2 (en) | 2013-12-20 | 2017-05-02 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015095444A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2017222951A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
KR20190140454A (en) | 2017-04-13 | 2019-12-19 | 아두로 바이오테크 홀딩스, 유럽 비.브이. | Anti-SIRP alpha antibody |
CN111315414A (en) | 2017-06-22 | 2020-06-19 | 梅尔莎纳医疗公司 | Methods of producing drug-loaded polymer scaffolds and protein-polymer-drug conjugates |
EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
CA3099419A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
AU2019262521B2 (en) | 2018-05-04 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
CN110194772B (en) | 2018-07-02 | 2022-04-05 | 深圳市塔吉瑞生物医药有限公司 | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity |
US11746110B2 (en) | 2018-07-17 | 2023-09-05 | Shenzhen Targetrx, Inc. | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity |
US20210309688A1 (en) | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
MX2021004906A (en) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Cysteine engineered antibody-drug conjugates with peptide-containing linkers. |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for high click release speed and yield |
JP2022537543A (en) | 2019-06-17 | 2022-08-26 | タグワークス ファーマシューティカルス ビー.ブイ. | Compounds for fast and efficient click release |
BR112022012032A2 (en) | 2019-12-17 | 2022-09-06 | Merck Sharp & Dohme Llc | PRMT5 INHIBITORS |
WO2023031445A2 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
DE4138042C2 (en) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilones, their production processes and agents containing these compounds |
DK0797988T3 (en) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US20030203976A1 (en) | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
EP0873341B1 (en) | 1995-11-17 | 2003-09-10 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone derivatives, preparation and use |
DE19542986A1 (en) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as cytostatics |
DE19639456A1 (en) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | New epothilone derivatives |
US5963145A (en) * | 1996-02-26 | 1999-10-05 | Universal Electronics Inc. | System for providing wireless pointer control |
DE19607702A1 (en) | 1996-02-29 | 1997-09-04 | Biotechnolog Forschung Gmbh | Heterocyclic compounds, manufacturing processes and agents |
PT932399E (en) | 1996-03-12 | 2006-05-31 | Pg Txl Co Lp | PRO-PHOSPHOLIC CAPSULES |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US20040106985A1 (en) * | 1996-04-26 | 2004-06-03 | Jang G. David | Intravascular stent |
US5917084A (en) | 1996-07-03 | 1999-06-29 | Millennium Pharmaceuticals, Inc. | Antifungal agents |
AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
DE19645362A1 (en) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Production of epothilone compounds with taxol-like activity |
US5969145A (en) | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
DE19636343C1 (en) | 1996-08-30 | 1997-10-23 | Schering Ag | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
DE19645361A1 (en) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Production of epothilone compounds with taxol-like activity |
DE19638870B4 (en) | 1996-09-23 | 2009-05-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tubulysins, methods for their production and agents containing them |
JP4274583B2 (en) | 1996-11-18 | 2009-06-10 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | Epothilone C, D, E and F, manufacturing and drugs |
JPH10150162A (en) * | 1996-11-18 | 1998-06-02 | Oki Electric Ind Co Ltd | Semiconductor device and its manufacture |
DE69734362T2 (en) * | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | SYNTHESIS OF EPOTHILONES, INTERMEDIATE PRODUCTS, ANALOGUES AND USES THEREOF |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (en) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | New beta-keto-alcohol derivatives |
DE19880193D2 (en) | 1997-02-25 | 2000-08-24 | Biotechnolog Forschung Gmbh | Side chain modified epothilones |
US20020086812A1 (en) | 1997-03-04 | 2002-07-04 | Schweinfest Clifford W. | Methods and compositions for diagnosis and treatment of cancer |
DE19713970B4 (en) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone Synthesis Building Blocks II - Prenyl Derivatives |
JP4065573B2 (en) | 1997-04-18 | 2008-03-26 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
DE19849464A1 (en) | 1997-04-30 | 2000-04-27 | Schering Ag | Stent with polymeric coating having pockets, preferably cyclodextrin stuctures, containing active agent for prophylaxis of restenosis |
US6117659A (en) | 1997-04-30 | 2000-09-12 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
DE19720312A1 (en) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Preparation with increased in vivo tolerance |
DE19821954A1 (en) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Preparation of epothilone derivatives |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US20030049841A1 (en) | 1997-06-16 | 2003-03-13 | Short Jay M. | High throughput or capillary-based screening for a bioactivity or biomolecule |
DE19726627A1 (en) | 1997-06-17 | 1998-12-24 | Schering Ag | New intermediates for epothilone |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ATE224882T1 (en) | 1997-07-16 | 2002-10-15 | Schering Ag | THIAZOLE DERIVATIVES, METHOD OF PRODUCTION AND USE |
DE19735578A1 (en) | 1997-08-09 | 1999-02-11 | Schering Ag | New di:hydroxy-hexanone or -pentene derivatives |
CA2299608A1 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
DE19751200A1 (en) | 1997-11-13 | 1999-05-20 | Schering Ag | New epothilone derivatives |
DE19735574A1 (en) | 1997-08-09 | 1999-02-11 | Schering Ag | New 3-hydroxy-5-oxo-hexanoic acid derivatives |
DE19735575A1 (en) | 1997-08-09 | 1999-02-11 | Schering Ag | New di:hydroxy-butanal or -pentene derivatives |
DE19749717A1 (en) | 1997-10-31 | 1999-05-06 | Schering Ag | New epothilone derivatives |
DE19813821A1 (en) | 1998-03-20 | 1999-09-23 | Schering Ag | New epothilone derivatives |
DE19744135C1 (en) | 1997-09-29 | 1999-03-25 | Schering Ag | Medical implants coated with epothilone |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
HUP0100582A3 (en) | 1997-12-04 | 2003-03-28 | Bristol Myers Squibb Co | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
US6280999B1 (en) | 1998-01-23 | 2001-08-28 | Kosan Bioscience | Sorangium polyketide synthases and encoding DNA therefor |
US6090601A (en) | 1998-01-23 | 2000-07-18 | Kosan Bioscience | Sorangium polyketide synthase |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
CA2320182C (en) | 1998-02-05 | 2008-11-25 | Novartis Ag | Compositions containing organic compounds |
DE19804673A1 (en) | 1998-02-06 | 1999-08-12 | Studiengesellschaft Kohle Mbh | Process for the preparation of macrocyclic products by ring-closing diine metathesis |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (en) | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
NZ506742A (en) | 1998-02-25 | 2003-09-26 | Sloan Kettering Inst Cancer | Synthesis of desoxyepothilones and hydroxy acid derivative intermediates |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
DE19820599A1 (en) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as pharmaceuticals and in plant protection |
GB9810659D0 (en) | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
NZ508326A (en) | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
US6121029A (en) | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
DE19826988A1 (en) | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
AU4775299A (en) | 1998-06-22 | 2000-01-10 | Nicolaou, Kyriacos Costa | Desmethyl epothilones |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
DE19830060A1 (en) | 1998-06-30 | 2000-02-10 | Schering Ag | New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis |
DE19923001A1 (en) | 1999-05-13 | 2000-11-16 | Schering Ag | New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis |
JP2002525026A (en) | 1998-07-02 | 2002-08-13 | ザ ボード オブ リージェンツ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Methods for making polyketides |
CN1329668A (en) | 1998-10-02 | 2002-01-02 | 高山生物科学股份有限公司 | Polyketide synthase enzymes and recombinant DNA constructs therefor |
DE19846493A1 (en) | 1998-10-09 | 2000-04-13 | Biotechnolog Forschung Gmbh | DNA sequence coding for products involved in the biosynthesis of polyketide or heteropolyketide compounds, especially epothilone |
DE19848306A1 (en) | 1998-10-14 | 2000-04-20 | Schering Ag | High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates |
JP2003512013A (en) | 1998-10-29 | 2003-04-02 | コーサン バイオサイエンシーズ, インコーポレイテッド | Recombinant oleandride polyketide synthase |
US6303767B1 (en) | 1998-11-05 | 2001-10-16 | Kosan Biosciences, Inc. | Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
CA2352505C (en) | 1998-12-22 | 2009-04-07 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
AU754459B2 (en) | 1998-12-23 | 2002-11-14 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
CN1340053A (en) | 1999-02-11 | 2002-03-13 | 舍林股份公司 | Epothilon derivatives, method for the production and the use as pharmaceuticals |
DE19908763A1 (en) | 1999-02-18 | 2000-08-24 | Schering Ag | New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators |
AU776511B2 (en) * | 1999-02-18 | 2004-09-09 | Baylor University | Compositions and methods for use in targeting vascular destruction |
DE19908767A1 (en) | 1999-02-18 | 2000-10-19 | Schering Ag | New stable, modified epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease |
DE19908760A1 (en) | 1999-02-18 | 2000-08-24 | Schering Ag | New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators |
IL144519A0 (en) | 1999-02-18 | 2002-05-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
DE19908765A1 (en) | 1999-02-18 | 2000-08-24 | Schering Ag | New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease |
US6406722B1 (en) | 1999-02-18 | 2002-06-18 | Robert G. Gallaher | Method of treating viral infections and lesions with taxane compounds |
DE19954230A1 (en) | 1999-11-04 | 2001-11-15 | Schering Ag | New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease |
DE19907588A1 (en) | 1999-02-22 | 2000-08-24 | Biotechnolog Forschung Gmbh | New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
DE19930111A1 (en) | 1999-07-01 | 2001-01-04 | Biotechnolog Forschung Gmbh | New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis |
US20020058286A1 (en) | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU4017400A (en) | 1999-03-29 | 2000-10-16 | Bristol-Myers Squibb Company | A process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6603015B2 (en) | 1999-03-29 | 2003-08-05 | University Of Kansas | Synthesis of epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
ES2273688T3 (en) * | 1999-04-14 | 2007-05-16 | Dana-Farber Cancer Institute, Inc. | PROCEDURE AND COMPOSITION FOR CANCER TREATMENT. |
EP2308833A3 (en) * | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
PE20010116A1 (en) | 1999-04-30 | 2001-02-15 | Schering Ag | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION |
DE19921086A1 (en) | 1999-04-30 | 2000-11-02 | Schering Ag | New stable 6-alkenyl- or 6-alkynyl-epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease |
DE10015836A1 (en) | 2000-03-27 | 2001-10-11 | Schering Ag | New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis |
DE19954228A1 (en) | 1999-11-04 | 2001-09-13 | Schering Ag | New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis |
WO2001007439A2 (en) | 1999-07-22 | 2001-02-01 | Schering Aktiengesellschaft | Process for the production of epothiolone b and derivatives as well as intermediate products for this process |
GB9918429D0 (en) | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
WO2001016178A1 (en) | 1999-08-27 | 2001-03-08 | University Of Florida | MATERIALS AND METHODS FOR INHIBITION OF IgE PRODUCTION |
US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
US20020147197A1 (en) | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
CA2425620A1 (en) | 1999-10-08 | 2001-04-19 | The Scripps Research Institute | 13-alkyl epothilone derivatives |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
US20020045220A1 (en) | 1999-10-13 | 2002-04-18 | Chaitan Khosla | Biosynthesis of polyketide synthase substrates |
US20030036177A1 (en) | 2002-08-13 | 2003-02-20 | Joachim Strohhacker | Single colonies of myxobacteria cells |
WO2001064650A2 (en) | 2000-03-01 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research Center | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2001066154A2 (en) | 2000-03-09 | 2001-09-13 | Klar, Ulrich | Radioactively labeled epothilone derivatives, method for the production thereof, and their biochemical and pharmaceutical use |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) * | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
DE10020517A1 (en) | 2000-04-19 | 2001-10-25 | Schering Ag | New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease |
DE10020899A1 (en) | 2000-04-20 | 2001-10-25 | Schering Ag | New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease |
ES2332727T3 (en) | 2000-04-28 | 2010-02-11 | Kosan Biosciences, Inc. | EPOTILONE D CRYSTALINE. |
US6998256B2 (en) * | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
US6489314B1 (en) | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
EP1278882A4 (en) | 2000-05-02 | 2004-08-18 | Kosan Biosciences Inc | Overproduction hosts for biosynthesis of polyketides |
US20020045609A1 (en) | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
US20020137152A1 (en) | 2000-07-25 | 2002-09-26 | Daniel Santi | Fermentation process for epothilones |
AU2001283275A1 (en) | 2000-08-09 | 2002-02-18 | Kosan Biosciences, Inc. | Bio-intermediates for use in the chemical synthesis of polyketides |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
US7766956B2 (en) * | 2000-09-22 | 2010-08-03 | Boston Scientific Scimed, Inc. | Intravascular stent and assembly |
IL155306A0 (en) | 2000-10-13 | 2003-11-23 | Univ Mississippi | Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby |
EP1358144B1 (en) | 2000-10-16 | 2006-12-27 | R&D-Biopharmaceuticals | Epothilone synthesis components i: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone and epothilone derivatives |
DE10051136A1 (en) | 2000-10-16 | 2002-04-18 | Ludger A Wessjohann | New alpha-hydroxy-ketone derivatives, useful as intermediates for biologically active polyketides, terpenoids, epothilones and their derivatives |
US7070797B2 (en) | 2000-11-07 | 2006-07-04 | Dana Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers |
US20020169135A1 (en) | 2000-11-07 | 2002-11-14 | Pardee Arthur B. | Method of treating hematologic tumors and cancers |
US20040038324A1 (en) * | 2000-11-22 | 2004-02-26 | Atadja Peter Wisdom. | Epothilone resistant cell lines |
GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
CA2434526C (en) | 2001-01-25 | 2011-11-01 | Bristol Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
EP1353667A1 (en) | 2001-01-25 | 2003-10-22 | Bristol-Myers Squibb Company | Parenteral formulations containing epothilone analogs |
KR100851719B1 (en) | 2001-01-25 | 2008-08-11 | 브리스톨-마이어스스퀴브컴파니 | Methods of Administering Epothilone Analogs for The Treatment of Cancer |
US20030004338A1 (en) | 2001-02-01 | 2003-01-02 | Li Wen Sen | Process for the preparation of epothilone analogs |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
EP1385529A4 (en) | 2001-02-20 | 2007-05-09 | Bristol Myers Squibb Co | Treatment of refractory tumors using epothilone derivatives |
RU2003128312A (en) | 2001-02-20 | 2005-02-10 | Бристол-Маерс Сквибб Компани (Us) | EPOTHYLON DERIVATIVES USED FOR TREATMENT OF RESISTANT TUMORS |
MXPA03007466A (en) * | 2001-02-27 | 2003-12-08 | Gbf Ges F R Biotechnologische | Degradation of epothilones. |
CN1511036B (en) * | 2001-02-27 | 2010-05-05 | 诺瓦提斯公司 | Combination comprising signal transduction inhibitor and epothilone derivative |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
IL157333A0 (en) | 2001-03-19 | 2004-02-19 | Novartis Ag | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
US20020169125A1 (en) | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
IL157993A0 (en) | 2001-03-23 | 2004-03-28 | Napro Biotherapeutics Inc | Molecular conjugates for use in cancer treatment and methods for the preparation thereof |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
WO2002080846A2 (en) | 2001-04-03 | 2002-10-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
EP1389090A2 (en) | 2001-04-26 | 2004-02-18 | Board of Regents, The University of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
US20030023082A1 (en) | 2001-05-15 | 2003-01-30 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
JP2004532888A (en) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | Epothilone derivative |
CN1543356B (en) | 2001-06-25 | 2011-09-28 | 味之素株式会社 | Anti-tumor agent |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
DE10138348A1 (en) | 2001-08-03 | 2003-02-27 | Schering Ag | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and methods of preparation and use |
DE10138347A1 (en) | 2001-08-03 | 2003-02-27 | Schering Ag | Protected 3,5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and derivatives and methods of preparation |
US6933385B2 (en) | 2001-08-03 | 2005-08-23 | Schering Ag | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
WO2003018002A2 (en) * | 2001-08-23 | 2003-03-06 | Novartis Ag | Cyclopropyl and cyclobutyl epothilone analogs |
HUP0402341A3 (en) * | 2001-08-31 | 2005-11-28 | Bristol Myers Squibb Company P | Compositions containing thiazol-2-ylamines for the treatment of cancer |
PL369108A1 (en) * | 2001-09-06 | 2005-04-18 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
WO2003026744A1 (en) | 2001-09-25 | 2003-04-03 | Alcon, Inc. | The use of epothilones and analogs in conjunction with ophthalmic surgery |
JP4138417B2 (en) | 2001-09-28 | 2008-08-27 | 積水化学工業株式会社 | Method for synthesizing organometallic compounds |
WO2003029195A1 (en) | 2001-09-28 | 2003-04-10 | Sumika Fine Chemicals Co., Ltd. | Intermediates for epothilone derivative and process for producing these |
US7070964B2 (en) | 2001-11-15 | 2006-07-04 | Kosan Biosciences Incorporated | Epothilone compounds and methods for making the same |
AU2002360430A1 (en) | 2001-11-26 | 2003-06-10 | Kosan Biosciences, Inc. | 14-methyl-epothilones |
TWI287986B (en) | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
DE10164592A1 (en) | 2001-12-21 | 2003-07-03 | Schering Ag | C1-C6 epothilone fragments and process for the preparation of C1-C6 fragments of epothilones and their derivatives |
CA2471874A1 (en) | 2001-12-26 | 2003-07-17 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
AU2003235761A1 (en) | 2002-01-14 | 2003-07-24 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
EP1340498A1 (en) | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
AU2003218110A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
US6900208B2 (en) * | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
CN101389334A (en) * | 2002-05-20 | 2009-03-18 | 高山生物科学股份有限公司 | Methods to administer epothilone d |
WO2003105828A1 (en) * | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
WO2004014919A1 (en) * | 2002-08-02 | 2004-02-19 | Novartis Ag | Epothilone derivatives |
AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US6921769B2 (en) * | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
KR20050058507A (en) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2003298571B2 (en) * | 2002-09-04 | 2006-10-19 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors |
NZ539163A (en) * | 2002-09-04 | 2007-03-30 | Schering Corp | Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors |
ES2291665T3 (en) * | 2002-09-04 | 2008-03-01 | Schering Corporation | PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES. |
AU2003295332B2 (en) * | 2002-09-19 | 2007-01-18 | Merck Sharp & Dohme Corp. | Imidazopyridines as cyclin dependent kinase inhibitors |
JP4845380B2 (en) * | 2002-09-19 | 2011-12-28 | シェーリング コーポレイション | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
EP2287168B1 (en) * | 2002-09-23 | 2013-02-13 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
EP1542693A1 (en) * | 2002-09-23 | 2005-06-22 | Shering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
MY134589A (en) * | 2002-09-23 | 2007-12-31 | Schering Corp | Imidazopyrazines as cyclin dependent kinase inhibitors |
US20040058899A1 (en) * | 2002-09-25 | 2004-03-25 | Klimko Peter G. | Use of epothilones and analogs in conjunction with ophthalmic surgery |
WO2004030620A2 (en) * | 2002-09-30 | 2004-04-15 | Bristol-Myers Squibb Company | Novel tyrosine kinase inhibitors |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
SI1562941T1 (en) | 2002-11-07 | 2010-05-31 | Kosan Biosciences Inc | Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same |
TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
-
1997
- 1997-12-03 DE DE69734362T patent/DE69734362T2/en not_active Expired - Lifetime
- 1997-12-03 CA CA2273083A patent/CA2273083C/en not_active Expired - Lifetime
- 1997-12-03 EP EP03022736A patent/EP1386922B1/en not_active Expired - Lifetime
- 1997-12-03 WO PCT/US1997/022381 patent/WO1999001124A1/en active IP Right Grant
- 1997-12-03 AU AU57929/98A patent/AU756699B2/en not_active Ceased
- 1997-12-03 JP JP50109599A patent/JP4579351B2/en not_active Expired - Fee Related
- 1997-12-03 US US08/986,025 patent/US6242469B1/en not_active Expired - Lifetime
- 1997-12-03 EP EP97954055A patent/EP0977563B1/en not_active Expired - Lifetime
-
1998
- 1998-06-06 TW TW086118854A patent/TW504511B/en not_active IP Right Cessation
-
2000
- 2000-09-13 US US09/662,426 patent/US6300355B1/en not_active Expired - Lifetime
- 2000-10-11 US US09/686,158 patent/US6369234B1/en not_active Expired - Lifetime
- 2000-10-18 US US09/691,615 patent/US6284781B1/en not_active Expired - Lifetime
-
2001
- 2001-03-13 US US09/808,451 patent/US6656961B2/en not_active Ceased
- 2001-06-05 US US09/874,514 patent/US6849651B2/en not_active Expired - Fee Related
- 2001-12-04 US US10/004,571 patent/US6972335B2/en not_active Expired - Fee Related
-
2002
- 2002-01-28 US US10/058,695 patent/US6828340B2/en not_active Expired - Lifetime
-
2003
- 2003-02-25 US US10/374,805 patent/US6723854B2/en not_active Expired - Fee Related
- 2003-05-07 US US10/431,467 patent/US20040019089A1/en not_active Abandoned
- 2003-10-28 US US10/695,582 patent/US20040102495A1/en not_active Abandoned
-
2007
- 2007-01-04 US US11/649,750 patent/USRE41990E1/en not_active Expired - Lifetime
- 2007-01-11 US US11/652,383 patent/US7750164B2/en not_active Expired - Fee Related
-
2009
- 2009-09-28 JP JP2009222984A patent/JP2009298816A/en active Pending
-
2010
- 2010-05-28 US US12/790,064 patent/US20100240721A1/en not_active Abandoned
-
2011
- 2011-03-03 US US13/040,211 patent/US8481575B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41990E1 (en) | 1996-12-03 | 2010-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6300355B1 (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | |
US6204388B1 (en) | Synthesis of epothilones, intermediates thereto and analogues thereof | |
AU758526B2 (en) | Synthesis of epothilones, intermediates thereto and analogues therof | |
US20050043376A1 (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 67, 73, 76, 86 AND 87, DESCRIPTION, REPLACED BY NEW PAGES 67, 73, 76, 86 AND 87; PAGES 1/59-59/59, DRAWINGS, REPLACED BY NEW PAGES 1/76-76/76; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2273083 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1999 501095 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 57929/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997954055 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954055 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 57929/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997954055 Country of ref document: EP |